PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Cancer Research and Treatment10.4143/crt.2017.52920185041458-1461Pembrolizumab for Refractory Metastatic Myxofibrosarcoma: A Case ReportHaa-Na Song, Min Gyu Kang, Jeong Rang Park, Jin-Yong Hwang, Jung Hun Kang, Won Seop Lee, Gyeong-Won Leehttp://e-crt.org/upload/pdf/crt-2017-529.pdf, http://e-crt.org/journal/view.php?doi=10.4143/crt.2017.529, http://www.e-crt.org/upload/pdf/crt-2017-529.pdf
Current Oncology10.3390/curroncol280100782021281813-817Gemcitabine-Containing Chemotherapy for the Treatment of Metastatic Myxofibrosarcoma Refractory to Doxorubicin: A Case SeriesArielle Elkrief, Suzanne Kazandjian, Thierry Alcindorhttps://www.mdpi.com/1718-7729/28/1/78/pdf
Reactions Weekly10.1007/s40278-019-69032-z201917731276-276Pembrolizumabhttp://link.springer.com/content/pdf/10.1007/s40278-019-69032-z.pdf, http://link.springer.com/article/10.1007/s40278-019-69032-z/fulltext.html, http://link.springer.com/content/pdf/10.1007/s40278-019-69032-z.pdf
Reactions Weekly10.1007/s40278-019-60331-7201917481416-416Pembrolizumabhttp://link.springer.com/content/pdf/10.1007/s40278-019-60331-7.pdf, http://link.springer.com/article/10.1007/s40278-019-60331-7/fulltext.html, http://link.springer.com/content/pdf/10.1007/s40278-019-60331-7.pdf
Reactions Weekly10.1007/s40278-017-37034-1201716721217-217Pembrolizumabhttp://link.springer.com/article/10.1007/s40278-017-37034-1/fulltext.html, http://link.springer.com/content/pdf/10.1007/s40278-017-37034-1.pdf, http://link.springer.com/content/pdf/10.1007/s40278-017-37034-1.pdf
Reactions Weekly10.1007/s40278-019-71174-0201917781371-371Pembrolizumabhttp://link.springer.com/content/pdf/10.1007/s40278-019-71174-0.pdf, http://link.springer.com/article/10.1007/s40278-019-71174-0/fulltext.html, http://link.springer.com/content/pdf/10.1007/s40278-019-71174-0.pdf
Case Reports in Oncology10.1159/0005008562019122456-465AIHA and Pancytopenia as Complications of Pembrolizumab Therapy for Metastatic Melanoma: A Case ReportDan Ni, Fatmah AlZahrani, Michael Smyliehttps://www.karger.com/Article/Pdf/500856, https://www.karger.com/Article/Pdf/500856
Reactions Weekly10.1007/s40278-019-72338-x201917821169-169Imatinib/pembrolizumabhttp://link.springer.com/content/pdf/10.1007/s40278-019-72338-x.pdf, http://link.springer.com/article/10.1007/s40278-019-72338-x/fulltext.html, http://link.springer.com/content/pdf/10.1007/s40278-019-72338-x.pdf
Reactions Weekly10.1007/s40278-022-11419-1202218971182-182Gemcitabine/paclitaxel/pembrolizumabhttps://link.springer.com/content/pdf/10.1007/s40278-022-11419-1.pdf, https://link.springer.com/article/10.1007/s40278-022-11419-1/fulltext.html, https://link.springer.com/content/pdf/10.1007/s40278-022-11419-1.pdf
Frontiers in Oncology10.3389/fonc.2020.615298202010Case Report: Two Cases of Chemotherapy Refractory Metastatic Penile Squamous Cell Carcinoma With Extreme Durable Response to PembrolizumabJad Chahoud, William Paul Skelton, Philippe E. Spiess, Christine Walko, Jasreman Dhillon, Kenneth L. Gage, Peter A. S. Johnstone, Rohit K. Jainhttps://www.frontiersin.org/articles/10.3389/fonc.2020.615298/full